232 related articles for article (PubMed ID: 25335841)
1. Microbicides and their potential as a catalyst for multipurpose sexual and reproductive health technologies.
Karim QA; Baxter C; Karim SA
BJOG; 2014 Oct; 121 Suppl 5(0 5):53-61. PubMed ID: 25335841
[TBL] [Abstract][Full Text] [Related]
2. Topical microbicides--what's new?
Karim QA; Baxter C; Karim SA
J Acquir Immune Defic Syndr; 2013 Jul; 63 Suppl 2():S144-9. PubMed ID: 23764627
[TBL] [Abstract][Full Text] [Related]
3. Preservation HIV-1-specific IFNγ+ CD4+ T-cell responses in breakthrough infections after exposure to tenofovir gel in the CAPRISA 004 microbicide trial.
Mureithi MW; Poole D; Naranbhai V; Reddy S; Mkhwanazi NP; Sibeko S; Werner L; Abdool Karim Q; Abdool Karim S; Ndung'u T; Altfeld M;
J Acquir Immune Defic Syndr; 2012 Jun; 60(2):124-7. PubMed ID: 22362152
[TBL] [Abstract][Full Text] [Related]
4. Topical microbicides for prevention of sexually transmitted infections.
Obiero J; Mwethera PG; Wiysonge CS
Cochrane Database Syst Rev; 2012 Jun; (6):CD007961. PubMed ID: 22696373
[TBL] [Abstract][Full Text] [Related]
5. Recruitment of high risk women for HIV prevention trials: baseline HIV prevalence and sexual behavior in the CAPRISA 004 tenofovir gel trial.
Karim QA; Kharsany AB; Frohlich JA; Baxter C; Yende N; Mansoor LE; Mlisana KP; Maarschalk S; Arulappan N; Grobler A; Sibeko S; Omar Z; Gengiah TN; Mlotshwa M; Samsunder N; Karim SS
Trials; 2011 Mar; 12():67. PubMed ID: 21385354
[TBL] [Abstract][Full Text] [Related]
6. Disclosure of microbicide gel use to sexual partners: influence on adherence in the CAPRISA 004 trial.
Mngadi KT; Maarschalk S; Grobler AC; Mansoor LE; Frohlich JA; Madlala B; Ngcobo N; Abdool Karim SS; Abdool Karim Q
AIDS Behav; 2014 May; 18(5):849-54. PubMed ID: 24633715
[TBL] [Abstract][Full Text] [Related]
7. Assessing the implementation effectiveness and safety of 1% tenofovir gel provision through family planning services in KwaZulu-Natal, South Africa: study protocol for an open-label randomized controlled trial.
Mansoor LE; Abdool Karim Q; Mngadi KT; Dlamini S; Montague C; Nkomonde N; Mvandaba N; Baxter C; Gengiah TN; Samsunder N; Dawood H; Grobler A; Frohlich JA; Abdool Karim SS
Trials; 2014 Dec; 15():496. PubMed ID: 25527071
[TBL] [Abstract][Full Text] [Related]
8. Assessing adherence in the CAPRISA 004 tenofovir gel HIV prevention trial: results of a nested case-control study.
MacQueen KM; Weaver MA; van Loggerenberg F; Succop S; Majola N; Taylor D; Karim QA; Karim SA
AIDS Behav; 2014 May; 18(5):826-32. PubMed ID: 24647763
[TBL] [Abstract][Full Text] [Related]
9. Update on microbicide research and development - seeking new HIV prevention tools for women.
Mertenskoetter T; Kaptur PE
Eur J Med Res; 2011 Jan; 16(1):1-6. PubMed ID: 21345763
[TBL] [Abstract][Full Text] [Related]
10. A second chance for microbicides.
Baleta A
Lancet; 2007 Jul; 370(9581):17-8. PubMed ID: 17632853
[No Abstract] [Full Text] [Related]
11. CAPRISA 004 tenofovir microbicide trial: no impact of tenofovir gel on the HIV transmission bottleneck.
Valley-Omar Z; Sibeko S; Anderson J; Goodier S; Werner L; Arney L; Naranbhai V; Treurnicht F; Abrahams MR; Bandawe G; Swanstrom R; Karim QA; Karim SS; Williamson C
J Infect Dis; 2012 Jul; 206(1):35-40. PubMed ID: 22551813
[TBL] [Abstract][Full Text] [Related]
12. Overview of microbicides for the prevention of human immunodeficiency virus.
Abdool Karim SS; Baxter C
Best Pract Res Clin Obstet Gynaecol; 2012 Aug; 26(4):427-39. PubMed ID: 22386823
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women.
Abdool Karim Q; Abdool Karim SS; Frohlich JA; Grobler AC; Baxter C; Mansoor LE; Kharsany AB; Sibeko S; Mlisana KP; Omar Z; Gengiah TN; Maarschalk S; Arulappan N; Mlotshwa M; Morris L; Taylor D;
Science; 2010 Sep; 329(5996):1168-74. PubMed ID: 20643915
[TBL] [Abstract][Full Text] [Related]
14. Microbicides are promoted as offering a 'female-controlled' HIV prevention method: so can they revolutionize the HIV crisis of young women in Kenya?
Raphael MC
J Public Health (Oxf); 2012 Dec; 34(4):625-30. PubMed ID: 23055541
[No Abstract] [Full Text] [Related]
15. Trial participation disclosure and gel use behavior in the CAPRISA 004 tenofovir gel trial.
Succop SM; MacQueen KM; van Loggerenberg F; Majola N; Karim QA; Karim SS
AIDS Care; 2014; 26(12):1521-5. PubMed ID: 25285564
[TBL] [Abstract][Full Text] [Related]
16. Impact of an adherence intervention on the effectiveness of tenofovir gel in the CAPRISA 004 trial.
Mansoor LE; Karim QA; Werner L; Madlala B; Ngcobo N; Cornman DH; Amico KR; Fisher J; Fisher WA; Macqueen KM; Karim SS
AIDS Behav; 2014 May; 18(5):841-8. PubMed ID: 24633717
[TBL] [Abstract][Full Text] [Related]
17. Development of a combination microbicide gel formulation containing IQP-0528 and tenofovir for the prevention of HIV infection.
Ham AS; Ugaonkar SR; Shi L; Buckheit KW; Lakougna H; Nagaraja U; Gwozdz G; Goldman L; Kiser PF; Buckheit RW
J Pharm Sci; 2012 Apr; 101(4):1423-35. PubMed ID: 22227864
[TBL] [Abstract][Full Text] [Related]
18. Reformulated tenofovir gel for use as a dual compartment microbicide.
Dezzutti CS; Rohan LC; Wang L; Uranker K; Shetler C; Cost M; Lynam JD; Friend D
J Antimicrob Chemother; 2012 Sep; 67(9):2139-42. PubMed ID: 22581908
[TBL] [Abstract][Full Text] [Related]
19. Adherence in the CAPRISA 004 tenofovir gel microbicide trial.
Mansoor LE; Abdool Karim Q; Yende-Zuma N; MacQueen KM; Baxter C; Madlala BT; Grobler A; Abdool Karim SS
AIDS Behav; 2014 May; 18(5):811-9. PubMed ID: 24643315
[TBL] [Abstract][Full Text] [Related]
20. Drug concentrations after topical and oral antiretroviral pre-exposure prophylaxis: implications for HIV prevention in women.
Karim SS; Kashuba AD; Werner L; Karim QA
Lancet; 2011 Jul; 378(9787):279-81. PubMed ID: 21763939
[No Abstract] [Full Text] [Related]
[Next] [New Search]
